Data on Bristol-Myers Squibb’s Investigational Treatment for Alzheimer’s Disease Demonstrate Potential Therapeutic Window at Doses Below 100 mg in Phase II Safety and Tolerability Study

close

Get every new post delivered right to your inbox.

Original Source